Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
76.66%
Operating Margin
54.82%
Net Margin
53.79%
Efficiency Metrics
Revenue per Expense Ratio
2.21
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
105.98%
Income Tax Rate
-0.53%
EPS
0.5500000000
Balance Sheet Analysis
Current Ratio
1.65
Cash Ratio
0.18
Working Capital
$19.55M
Debt to Equity
0.70
Debt to Assets
35.35%
Equity Ratio
50.48%
Cash Flow Analysis
Operating Cash Flow Ratio
22.51%
Free Cash Flow Ratio
12.37%
CapEx to Revenue
10.14%
Dividends Paid
$12.27M
Stock Buybacks
$80.71M
Total Shareholder Returns
$92.98M
Cash Position Change
-28.29%
Key Takeaways (2023 FY)
Revenue declined by 6.1166476066002%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 7.28%
Detailed Growth Metrics
Core Performance
Revenue
-6.12%
Net Income
164.80%
EPS
243.75%
Operating Income
26.13%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
-15.63%
Operating Cash Flow
-24.42%
Free Cash Flow
0.64%
Balance Sheet Health
Assets
-11.91%
Debt
-17.37%
Book Value per Share
-9.16%
Inventory
-16.84%
Shareholder Returns
Dividends per Share
7.28%
Shares Outstanding
-1.39%
Long Term Trends
3Y Revenue/Share
-33.72%
5Y Revenue/Share
-34.39%
3Y Dividend/Share
-50.47%
5Y Dividend/Share
-63.29%